LATITUDE study and current perspectives in the treatment of metastatic, hormone-sensitive prostate cancer
MUDr. Tomáš Blažek
Radioterapeutická a onkologická klinika, 3. LF UK a FN Královské Vinohrady, Praha
Therapy of prostate cancer has improved significantly over the past 10 years. In the treatment of localized stages, the emphasis is on the quality of life of patients after radical treatment and the effort to minimize late adverse effects of treatment. Patients achieve very good treatment results and their overall and cancer-specific survival is significantly better compared to other malignancies. A similar trend is seen in patients with metastatic disease. Advances in palliative systemic therapy noticeably changed and improved overall and cancer-specific survival. The new generation of antiandrogens offers patients with metastatic prostate cancer new perspectives not only in terms of survival but especially in the quality of life during treatment. The aim of this article is to provide an overview of current treatment options for metastatic, hormone-sensitive prostate cancer.
prostate cancer, androgen deprivation therapy, hormonal therapy, antiandrogens of new generation, abiraterone acetate, enzalutamide, docetaxel, chemotherapy, orchiectomy, external beam therapy
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...